BR112015010941A2 - pró-fármacos de gemcitabina e suas utilizações - Google Patents

pró-fármacos de gemcitabina e suas utilizações

Info

Publication number
BR112015010941A2
BR112015010941A2 BR112015010941A BR112015010941A BR112015010941A2 BR 112015010941 A2 BR112015010941 A2 BR 112015010941A2 BR 112015010941 A BR112015010941 A BR 112015010941A BR 112015010941 A BR112015010941 A BR 112015010941A BR 112015010941 A2 BR112015010941 A2 BR 112015010941A2
Authority
BR
Brazil
Prior art keywords
substituted
group
cycloheteroalkyl
formula
compounds
Prior art date
Application number
BR112015010941A
Other languages
English (en)
Inventor
I Wu Laurence
Original Assignee
Boyen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boyen Therapeutics Inc filed Critical Boyen Therapeutics Inc
Publication of BR112015010941A2 publication Critical patent/BR112015010941A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

resumo “pró-fármacos de gemcitabina e suas utilizações” a presente invenção proporciona compostos de acordo com a fórmula i e seus sais farmaceuticamente aceitáveis. para os compostos de fórmula i, r1 e r2 são independentemente selecionados a partir do grupo que consiste em h, -c(=o)(ch2)2-arilo, e c(=o)(ch2)n-c(=o)nh-arilo . o índice n é de 2 a 6. r3 é selecionado a partir do grupo que consiste em h e -c(=o)-o-r4; e r4 é selecionado a partir do grupo que consiste em alquilo, alquilo substituído, alcenilo, alcenilo substituído, alcinilo, alcinilo substituído, arilalquilo, arilalquilo substituído, ciclo-heteroalquilo, ciclo-heteroalquilo substituo, heteroalquilo substituo e heteroalquilo. os compostos são fornecidos em que pelo menos um de r1 e r2 é diferente de h. composições farmacêuticas, métodos para a inibição do crescimento de células cancerosas, e métodos para o tratamento do cancro são também fornecidos.
BR112015010941A 2012-11-13 2013-11-12 pró-fármacos de gemcitabina e suas utilizações BR112015010941A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261725643P 2012-11-13 2012-11-13
PCT/US2013/069640 WO2014078295A1 (en) 2012-11-13 2013-11-12 Gemcitabine prodrugs and uses thereof

Publications (1)

Publication Number Publication Date
BR112015010941A2 true BR112015010941A2 (pt) 2017-07-11

Family

ID=50681903

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015010941A BR112015010941A2 (pt) 2012-11-13 2013-11-12 pró-fármacos de gemcitabina e suas utilizações

Country Status (10)

Country Link
US (3) US8956613B2 (pt)
EP (1) EP2919790B1 (pt)
JP (1) JP6420247B2 (pt)
KR (1) KR20150082606A (pt)
CN (1) CN104968353B (pt)
AU (1) AU2013345007B2 (pt)
BR (1) BR112015010941A2 (pt)
CA (1) CA2891124A1 (pt)
SG (1) SG11201503773SA (pt)
WO (1) WO2014078295A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8956613B2 (en) 2012-11-13 2015-02-17 BoYen Therapeutics, Inc. Gemcitabine prodrugs and uses thereof
EP3125920B1 (en) 2014-04-04 2020-12-23 Del Mar Pharmaceuticals Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer
WO2016078397A1 (zh) * 2014-11-17 2016-05-26 常州方圆制药有限公司 新型胞苷衍生物及其应用
WO2016078163A1 (zh) * 2014-11-17 2016-05-26 常州方圆制药有限公司 新型胞苷衍生物二聚体及其应用
WO2016078160A1 (zh) * 2014-11-17 2016-05-26 常州方圆制药有限公司 胞苷衍生物及其应用
WO2016078399A1 (zh) * 2014-11-17 2016-05-26 常州方圆制药有限公司 新型胞苷衍生物二聚体及其应用
ITUB20159671A1 (it) * 2015-12-22 2017-06-22 Maurizio Ceruti Carbammati lipidici di farmaci antitumorali
HUE050290T2 (hu) * 2015-12-23 2020-11-30 NuCana plc Kombinált terápia
CN106946960A (zh) * 2017-03-29 2017-07-14 郑州泰基鸿诺医药股份有限公司 一种吉西他滨前药的晶型、制备方法、用途和药物组合物
CN110831605A (zh) 2017-04-26 2020-02-21 托马斯·I.·卡尔曼 多靶标的核苷衍生物
CN108329371B (zh) * 2018-03-06 2021-04-09 沈阳药科大学 白蛋白结合型吉西他滨前药及其合成和应用
WO2019204869A1 (en) * 2018-04-26 2019-10-31 NanoMed Holdings Pty Ltd Gemcitabine amphiphile prodrugs
GR1009958B (el) * 2019-04-24 2021-03-18 ΕΝΟΡΑΣΙΣ ΑΝΩΝΥΜΗ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΚΑΙ ΙΑΤΡΙΚΩΝ ΥΛΙΚΩΝ ΚΑΙ ΜΗΧΑΝΗΜΑΤΩΝ με δ.τ. "ΕΝΟΡΑΣΙΣ Α.Ε." Παραγωγα γεμσιταβινης και μεθοδοι δημιουργιας παραγωγων γεμσιταβινης
CN114011581B (zh) * 2021-11-09 2023-03-24 昆明理工大学 一种弱酸性条件下铜硫分离的抑制剂制备方法及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814438A (en) 1986-12-24 1989-03-21 Eli Lilly And Company Immunoglobulin conjugates of 2',2'-difluronucleosides
US4994558A (en) 1986-12-24 1991-02-19 Eli Lilly And Company Immunoglobulin conjugates
GB2321454A (en) 1997-01-24 1998-07-29 Norsk Hydro As Gemcitabine esters and amides
CA2278056C (en) * 1997-01-24 2006-12-12 Norsk Hydro Asa Gemcitabine derivatives
US6376470B1 (en) 1999-09-23 2002-04-23 Enzon, Inc. Polymer conjugates of ara-C and ara-C derivatives
US7265096B2 (en) 2002-11-04 2007-09-04 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
GB0321613D0 (en) 2003-09-15 2003-10-15 Drug Discovery Lab As Compounds
FR2874016B1 (fr) 2004-06-30 2006-11-24 Centre Nat Rech Scient Cnrse Nanoparticules de derives de la gemcitabine
WO2006029081A2 (en) 2004-09-02 2006-03-16 Neopharm, Inc. Nucleoside-lipid conjugates, their method of preparation and uses thereof
EP1804838A2 (en) 2004-09-15 2007-07-11 Drug Discovery Laboratory AS Drug conjugates of long chain fatty acid or ester moieties as protein binding prodrugs
US7691827B2 (en) 2004-12-17 2010-04-06 Eli Lilly And Company Amide prodrug of gemcitabine, compositions and use thereof
NO322682B1 (no) 2005-03-18 2006-11-27 Clavis Pharma Asa Anvendelse av gemcitabinderivater for fremstilling av orale doseringsformer ved kreftbehandling, samt slike orale doseringsformer
AT502221A1 (de) 2005-07-20 2007-02-15 Pharmacon Forschung & Beratung Gmbh Homogemcitabine, verfahren zu ihrer herstellung sowie deren verwendung
MX2009000198A (es) 2006-06-21 2009-01-22 Lilly Co Eli Formas cristalinas de profarmaco amida de gemcitabina, composiciones y usos del mismo.
CN101209350B (zh) 2006-12-30 2011-09-07 中国人民解放军军事医学科学院毒物药物研究所 以氨基酸为连接子的多聚谷氨酸-药物偶合物
WO2010039039A1 (en) 2008-10-03 2010-04-08 Clavis Pharma Asa Oral formulations of gemcitabine derivatives
CA2739757C (en) 2008-10-07 2016-07-05 Rexahn Pharmaceuticals, Inc. Hpma - docetaxel or gemcitabine conjugates and uses therefore
CN101525361B (zh) 2009-04-21 2010-11-17 济南圣鲁金药物技术开发有限公司 基于吉西他滨结构的前药及其合成方法及应用
US20120142720A1 (en) * 2009-07-02 2012-06-07 Kempharm, Inc. Phenylethanoic Acid, Phenylpropanoic Acid and Phenylpropenoic Acid Conjugates and Prodrugs of Hydrocodone, Methods of Making and Use Thereof
MX2012005677A (es) 2009-11-20 2012-08-23 Clavis Pharma Asa Formulaciones parentales de derivados de gemcitabina.
GB201016855D0 (en) 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
WO2012098557A1 (en) 2011-01-20 2012-07-26 Institute Of Life Sciences Pegylated gemcitabine derivative and process for preparing the same
WO2013019945A2 (en) 2011-08-02 2013-02-07 Clovis Oncology, Inc.. Method for selection of chemotherapeutic agents for adenocarcinoma cancer
CN102432654A (zh) 2011-09-26 2012-05-02 宋云龙 吉西他滨酰胺衍生物及其制备方法和用途
US8956613B2 (en) 2012-11-13 2015-02-17 BoYen Therapeutics, Inc. Gemcitabine prodrugs and uses thereof
CN103130854A (zh) 2013-01-31 2013-06-05 华东师范大学 维生素e琥珀酸酯化吉西他滨前药及应用

Also Published As

Publication number Publication date
US9890189B2 (en) 2018-02-13
SG11201503773SA (en) 2015-06-29
US20140134160A1 (en) 2014-05-15
JP6420247B2 (ja) 2018-11-07
EP2919790B1 (en) 2018-04-04
CA2891124A1 (en) 2014-05-22
JP2016503414A (ja) 2016-02-04
US8956613B2 (en) 2015-02-17
WO2014078295A8 (en) 2015-05-21
WO2014078295A1 (en) 2014-05-22
US20170107245A1 (en) 2017-04-20
AU2013345007B2 (en) 2018-08-30
EP2919790A4 (en) 2016-04-06
US9540410B2 (en) 2017-01-10
EP2919790A1 (en) 2015-09-23
CN104968353B (zh) 2017-12-22
US20150132298A1 (en) 2015-05-14
KR20150082606A (ko) 2015-07-15
CN104968353A (zh) 2015-10-07
AU2013345007A1 (en) 2015-05-21

Similar Documents

Publication Publication Date Title
BR112015010941A2 (pt) pró-fármacos de gemcitabina e suas utilizações
BRPI1013821A8 (pt) piridinas substituídas como antagonistas de ccr3.
CA2875877C (en) Syk inhibitors
UY32096A (es) Derivados de 2-carboxamida - cicloamino - urea especìficos, sus sales farmacèuticamente aceptables, composiciones contenièndolos, pro-farmacos de los mismos, procesos para su produciòn y aplicaciones
BR112015032921A8 (pt) compostos de benzofuranila e benzoxazolila substituídos e utilizações dos mesmos
MA34644B1 (fr) Dérivés de pyrazole aminopyrimidine en tant que modulateurs du lrrk2
CO6470845A2 (es) Derivados de pirimidina novedosos y su uso en el tratamiento del cancer y enfermedades adicionales
BR112015028501B8 (pt) Compostos derivados de bipirazol, seus sais, composição compreendendo o composto ou o sal, método de inibição in vitro de uma atividade de jak1, e processo de preparação de sal de ácido fosfórico
BR112014005226A2 (pt) derivados de benzonitrila como inibidores de cinase
BR112014002612A2 (pt) composições compreendendo monoésteres de isossorbida e hidroxipiridonas
BR112015022861A8 (pt) inibidores de bromodomínio
BR112012030820A8 (pt) Derivados de aminopirimidina como moduladores de lrrk2, seu uso e composição que os compreende
CR11793A (es) 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas
UY33587A (es) Nuevos compuestos como inhibidores de quinasas syk y jak
EA201001618A1 (ru) Ингибиторы syk протеинкиназ
DOP2014000012A (es) Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa
BR112015001839A2 (pt) ibrutinibe deuterado
BR112013031405A2 (pt) piridopirazinas substituídas como novos inibidores de syk
BR112012029647A2 (pt) novos derivados de pirimidinas
BR112015016325A2 (pt) Composto, composição farmacêutica, e, usos de uma composição, composto, pró-droga ou sal farmaceuticamente aceitável do mesmo
EA201600337A1 (ru) 2,6-замещенные пуриновые производные и их применение в лечении пролиферативных заболеваний
BR112017006093A2 (pt) moduladores alostéricos negativos de n-alquilaril-5-oxiaril-octa-hidro-ciclopenta[c] pirrol de nr2b
MX337440B (es) Antagonistas de trpv4.
MX344933B (es) Compuestos de lipoílo y su uso para tratar lesión isquémica.
BR112012031340A2 (pt) derivados de cianoquinolina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]